Surrozen (SRZN) Shares Outstanding (2020 - 2026)
Surrozen (SRZN) posted quarterly Shares Outstanding (Entity) of $10949.0 for Q1 2026, up 201.79% year-over-year from $3628.0 in Q1 2025, and up 46.42% quarter-over-quarter from $7478.0 in Q4 2025.
Surrozen (SRZN) Shares Outstanding (2020 - 2026) Analysis & Trends
Surrozen's Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $10949.0 for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 201.79% year-over-year to $10949.0; the TTM figure through Mar 2026 stood at $10949.0 (up 201.79% YoY), while the FY2025 annual figure was $7478.0, up 154.96% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $10949.0, up from $7478.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $3.2 million in Q3 2024, with the low at $1998.0 in Q1 2023.
- The 5-year median for Shares Outstanding (Entity) is $3628.0 (2025), against an average of $622947.2.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) plunged 99.87% in 2022, then surged 87375.06% in 2023.
- Surrozen's Shares Outstanding (Entity) stood at $2315.0 in 2022, then retreated by 12.83% to $2018.0 in 2023, then soared by 45.34% to $2933.0 in 2024, then jumped by 154.96% to $7478.0 in 2025, then soared by 46.42% to $10949.0 in 2026.
- Business Quant data shows SRZN's Shares Outstanding (Entity) at $10949.0 in Q1 2026, $7478.0 in Q4 2025, and $8571.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 11.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.66 Mn |
| Mar 31, 2026 | 10,949.00 |
| Dec 31, 2025 | 7,478.00 |
| Sep 30, 2025 | 8,571.00 |
| Jun 30, 2025 | 8,541.00 |
| Mar 31, 2025 | 3,628.00 |
| Dec 31, 2024 | 2,933.00 |
| Sep 30, 2024 | 3.23 Mn |
| Jun 30, 2024 | 3.16 Mn |
| Mar 31, 2024 | 2,083.00 |
| Dec 31, 2023 | 2,018.00 |
| Sep 30, 2023 | 2.03 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 1,998.00 |
| Dec 31, 2022 | 2,315.00 |
| Sep 30, 2022 | 2,331.00 |
| Jun 30, 2022 | 2,330.00 |
| Mar 31, 2022 | 2,324.00 |
| Dec 31, 2021 | 1.65 Mn |
| Sep 30, 2021 | 1.83 Mn |